InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.18
(
-0.25%
)
Bitcoin
63,647.69
(
-0.93%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

cooldrinkh2o

Send PM Follow Ignore
Followers 0
Posts 113
Boards Moderated 0
Alias Born 05/28/2005

cooldrinkh2o

Re: tony111 post# 167845

Wednesday, 10/09/2013 3:39:33 PM

Wednesday, October 09, 2013 3:39:33 PM

Post# of 252311
Inclusig will likely be second line if pt fails tasigna


The DC rates for the ABLs are close to 20% and the AE profiles are different enough that I think Iclusig will still get use. The uptake curve, however, will likely become more shallow - closer to the original nilotinib uptake curve.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up